Project Grant K99CA303346
Award Date
7/1/25
Completion Date
6/30/27
Dollars Obligated
$176K
Federal Agency
National Cancer Institute
Federal Grant Program
93.398
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding to The General Hospital Corporation, doing business as Massachusetts General Hospital, to conduct a Phase I clinical trial evaluating the safety and feasibility of CARV3.TEAM-E cells for the treatment of primary or recurrent glioblastoma (GBM), a deadly brain tumor. The CARV3.TEAM-E cells are genetically engineered chimeric antigen receptor (CAR) T cells that target the...
This $195,766 federal Project Grant, awarded on December 19, 2024 by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), supports research at Yale University to develop a mechano-transduction platform for enhancing chimeric antigen receptor (CAR) T-cell therapies for cancer immunotherapy. The key goals are to: 1) measure forces along immune receptors like the T-cell receptor and CAR using force sensors, and 2) engineer force transduction modules that can induce expression of...
This $1,108,391.72 Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports research to define the most therapeutically relevant chimeric antigen receptor (CAR) T cell subsets for treating large B cell lymphoma (LBCL) and overcome immune suppression mechanisms that limit CAR T cell efficacy. The funded project will use a systems biology approach to analyze patient data and pinpoint optimal CAR T cell characteristics for...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to harness B cells after stem cell transplant to produce novel chimeric antigen receptor T-cells (CAR-Ts) for treating hematological malignancies. The $415,257 award to Duke University, a leading research institution, will fund research to clone antibody-producing B cells with tumor-binding potential after hematopoietic stem cell transplantation. The goal is to engineer less toxic and...
The National Cancer Institute (NCI) awarded a $162,486 Project Grant under the Cancer Research Manpower (CFDA 93.398) federal grant program to the University of Pittsburgh. The project aims to investigate the functional consequences of high glucose culture on adoptive T cell therapies for cancer. Specifically, the research will (1) identify cellular proteins that are differentially O-GlcNAcylated under high glucose conditions and determine if inhibiting O-GlcNAcylation can restore T cell...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $604,627 to the Trustees of Dartmouth College to conduct research aimed at deconvoluting the heterogeneity of chimeric antigen receptor (CAR) T cells in order to engineer durable antitumor immunity. The research project, which runs from January 1, 2025 to December 31, 2029, will use dynamic lineage recording to understand how individual CAR T cell subsets behave in vivo and...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $249,645 to Boston Children's Hospital to develop advanced genetic engineering techniques to study the role of tumor-specific B cells in cancer progression. The researchers aim to genetically modify B cells to target the HER2 tumor antigen, with the goal of using these engineered B cells as an adoptive immunotherapy to trigger both humoral and cellular anti-tumor immune responses. The...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $218,089 to the University of California, Santa Barbara to develop and evaluate a novel Chimeric Antigen Receptor Macrophage (CAR-M) immunotherapy targeting triple-negative breast cancer (TNBC). The key goals are to: 1) Evaluate the specificity, efficacy, and impact on angiogenesis of an anti-CSPG4 Rac-enhanced CAR-M (RACE-CAR-M) therapy using in vivo chicken chorioallantoic membrane...
The National Cancer Institute (NCI), under the federal Cancer Treatment Research Grant Program (CFDA 93.395), awarded a $398,997 Project Grant to Immunogenik, Inc. in Gainesville, Florida. The grant supports the development and evaluation of a "3-in-1" Chimeric Antigen Receptor (CAR) T-cell therapy to enhance cancer treatment. The project aims to overcome limitations of current cancer therapies by targeting tumor-associated myeloid cells, which play a key role in cancer...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the Sloan-Kettering Institute for Cancer Research provides $1,313,806.00 in funding from August 13, 2024 through July 31, 2029. The grant supports the development and clinical translation of mesothelin-targeted chimeric antigen receptor (CAR) T-cell therapies for solid tumors. Key objectives include: Elucidating the mechanisms by which the KITV costimulatory domain enhances CAR T-cell...